Table 3.

Best overall response in patients with solid malignancies

Utomilumab
N = 53
Complete response (CR)1 (1.9)
Partial response (PR)1 (1.9)
Stable disease13 (24.5%)
Disease progression34 (64.2%)
Not evaluablea4 (7.5%)
Objective response rate (CR + PR) [95% exact CI]2 (3.8) [0.5–13.0]
  • aOf the four nonevaluable patients, one had inadequate baseline assessments, two had no post-baseline assessments due to death (n = 1) or other reason (n = 1), and one started a new anticancer therapy prior to the first post-baseline assessment.